Evolving landscape in the management of transthyretin amyloidosis

References

• Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31–8.
   PubMed Web of Science ®Google Scholar
• Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science. 1995; 268:1039–41.
   PubMed Web of Science ®Google Scholar
• Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223–41.
   PubMed Web of Science ®Google Scholar
• Westermark P, Sletten K, Johansson B, Cornwell GG. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990;87:2843–5.
   PubMed Web of Science ®Google Scholar
• Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411–23.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyreting amyloidosis. Curr Med Res Opin. 2013;29:63–76.
   PubMed Web of Science ®Google Scholar
• Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33:1120–7.
   PubMed Web of Science ®Google Scholar
• Benson MD, Teague SD, Kovacs R, Feigenbaum H, Jung J, Kincaid JC. Rate of progression of transthyretin amyloidosis. Am J Cardiol. 2011;108:285–9.
   PubMed Web of Science ®Google Scholar
• Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83:152–8.
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and Val122Ile mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164:222–8.
   PubMed Web of Science ®Google Scholar
• Stewart M, Lenderking W, Loftus J, Murphy B, Alvir J, Shaffer S, et al. Evaluating the quality of life and burden of illness in an ultra-rare disease in the U.S.: transthyretin familial amyloid polyneuropathy (TTR-FAP) patients and caregivers. IXth International Symposium on Familial Amyloidotic Polyneuropathy (ISFAP), Rio de Janeiro, Brazil; 10–13 November 2013 [Poster No. E-16].
   Google Scholar
• Stewart M, Loftus J, Lenderking W, Murphy B, Alvir J, Shaffer S, et al. Characterizing disease burden in an ultra-rare disease in the U.S.: transthyretin (TTR) amyloidosis patients and caregivers. ISPOR 16th Annual European Congress, Dublin, Ireland; 4–6 November 2013 [Poster No. PSY49].
   Google Scholar
• Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78–84.
   PubMed Web of Science ®Google Scholar
• Adams D, Lozeron P, Lacroix C. Amyloid neuropathies. Curr Opin Neurol. 2012;25:564–72.
   PubMed Web of Science ®Google Scholar
• Dohrn MF, Rocken C, De Bleecker JL, Martin JJ, Vorgerd M, Van den Bergh PY, et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol. 2013;260: 3093–108.
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69:693–8.
   PubMed Web of Science ®Google Scholar
• Hamour IM, Lachmann HJ, Goodman HJ, Petrou M, Burke MM, Hawkins PN, et al. Heart transplantation for homozygous familial transthyretin (TTR) Val122Ile cardiac amyloidosis. Am J Transplant. 2008;8:1056–9.
   PubMed Web of Science ®Google Scholar
• Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc. 2012;60:765–74.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Sekijima Y, Tojo K, Koyama J. Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis. Amyloid. 2011;18:211–15.
   PubMed Web of Science ®Google Scholar
• van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006;54:2015–21.
   PubMed Web of Science ®Google Scholar
• Do AB, Coelho T, Sousa A, Guimaraes A. Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. Amyloid. 2009;16:232–8.
   PubMed Web of Science ®Google Scholar
• Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113:1723–7.
   PubMed Web of Science ®Google Scholar
• Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N, et al. Rapid progression of familial amyloid polyneuropathy: a multinational natural history study. Neurology. 2015;85:675–82.
   PubMed Web of Science ®Google Scholar
• Rosenzweig M, Landau H. Light chain (AL) amyloidosis: update on diagnosis and management. J Hematol Oncol. 2011;4:47–54.
   PubMed Web of Science ®Google Scholar
• Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin Val30Met amyloidosis. J Pathol. 2008;216:253–61.
   PubMed Web of Science ®Google Scholar
• Aljaroudi WA, Desai MY, Tang WH, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol. 2014;21:271–83.
   PubMed Web of Science ®Google Scholar
• Ihse E, Rapezzi C, Merlini G, Benson MD, Ando Y, Suhr OB, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid. 2013;20: 142–50.
   PubMed Web of Science ®Google Scholar
• Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014;39:225–33.
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336: 466–73.
   PubMed Web of Science ®Google Scholar
• Olsson M, Jonasson J, Cederquist K, Suhr OB. Frequency of the transthyretin Val30Met mutation in the northern Swedish population. Amyloid. 2014;21:18–20.
   PubMed Web of Science ®Google Scholar
• Carvalho F, Sousa M, Fernandes S, Silva J, Saraiva MJ, Barros A. Preimplantation genetic diagnosis for familial amyloidotic polyneuropathy (FAP). Prenat Diagn. 2001;21:1093–9.
   PubMed Web of Science ®Google Scholar
• Morris M, Nicholes W, Benson M. Prenatal diagnosis of hereditary amyloidosis in a Portugese family. Am J Med Genet. 1991;39:123–4.
   PubMed Web of Science ®Google Scholar
• Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008;15:181–6.
   PubMed Web of Science ®Google Scholar
• Misu K, Hattori N, Nagamatsu M, Ikeda S, Ando Y, Nakazato M, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain. 1999;122(Pt 10):1951–62.
   Google Scholar
• Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–97.
   PubMed Web of Science ®Google Scholar
• Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994;235:479–85.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120:1203–12.
   PubMed Web of Science ®Google Scholar
• Lindqvist P, Olofsson BO, Backman C, Suhr O, Waldenstrom A. Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr. 2006;7:22–30.
   PubMed Web of Science ®Google Scholar
• Dungu J, Sattianayagam PT, Whelan CJ, Gibbs SD, Pinney JH, Banypersad SM, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J. 2012;164:72–9.
   PubMed Web of Science ®Google Scholar
• Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7:157–65.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38:470–8.
   PubMed Web of Science ®Google Scholar
• Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–84.
   PubMed Web of Science ®Google Scholar
• Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15:1289–98.
   PubMed Web of Science ®Google Scholar
• Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195–201.
   PubMed Web of Science ®Google Scholar
• Kato-Motozaki Y, Ono K, Shima K, Morinaga A, Machiya T, Nozaki I, et al. Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus. J Neurol Sci. 2008;270:133–40.
   PubMed Web of Science ®Google Scholar
• Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62:1057–62.
   PubMed Web of Science ®Google Scholar
• Suanprasert N, Berk JL, Benson MD, Dyck PJ, Klein CJ, Gollob JA, et al. Retrospective study of a TTR FAP cohort to modify NIS + 7 for therapeutic trials. J Neurol Sci. 2014;344:121–8.
   PubMed Web of Science ®Google Scholar
• Riboldi G, Del Bo R, Ranieri M, Magri F, Sciacco M, Moggio M, et al. Tyr78Phe transthyretin mutation with predominant motor neuropathy as the initial presentation. Case Rep Neurol. 2011;3:62–8.
   PubMedGoogle Scholar
• Hornsten R, Pennlert J, Wiklund U, Lindqvist P, Jensen SM, Suhr OB. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid. 2010;17:63–8.
   PubMed Web of Science ®Google Scholar
• Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002;59:1771–6.
   PubMed Web of Science ®Google Scholar
• Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. p. 88–93.
   Google Scholar
• Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–67.
   PubMed Web of Science ®Google Scholar
• Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Rodrigues Pena J, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99:1847–54.
   PubMed Web of Science ®Google Scholar
• Ramalho A, Cortez-Dias N, Guimaraes T, Francisco AG, Nobre Menezes M, Lima Silva G, et al. Prognostic analysis of heart rate variability assessment in familial amyloid polyneuropathy. Eur Heart J. 2014;35(Suppl):933 [Abstract P5268].
   Google Scholar
• Ramalho A, Cortez-Dias N, Lima Silva G, Placido R, Guimaraes T, Francisco AG, et al. Progression of cardiomyopathy in familial amyloid polyneuropathy – impact on prognosis. Eur Heart J. 2014;35(Suppl.):1058 [Abstract P5971].
   Google Scholar
• Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232–9.
   PubMed Web of Science ®Google Scholar
• Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2:113–22.
   PubMed Web of Science ®Google Scholar
• Dharmarajan K, Salomon S, Helmke S, Tereyua S, Rapezzi C, Falk R, et al. Genotype and phenotypic characteristics of persons with cardiac amyloidosis from the Multinational Transthyretin Amyloidosis Survey (THAOS) registry. J Cardiac Fail. 2014;117(Suppl):S69 [Abstract 221].
   Google Scholar
• Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286–300.
   PubMed Web of Science ®Google Scholar
• Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and Val122Ile transthyretin in older adults referred to an academic medical center. Aging Health. 2013;9: 229–35.
   PubMedGoogle Scholar
• Damy T, Jaccard A, Guellich A, Lavergne D, Rappeneau S, Deux JF, et al. Comparison and identification of early clinical, biological and echocardiographic prognostic markers in transthyretin and AL cardiac amyloidosis. Eur Heart J. 2014;35(Suppl):668 [Abstract P3655].
   Google Scholar
• Adams D. Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord. 2013;6:129–39.
   PubMed Web of Science ®Google Scholar
• Algalarrondo V, Dinanian S, Juin C, Chemla D, Bennani SL, Sebag C, et al. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm. 2012;9:1069–75.
   PubMed Web of Science ®Google Scholar
• Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63:1285–8.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985;55:1645.
   PubMed Web of Science ®Google Scholar
• Piccirillo G, Nocco M, Lionetti M, Moise A, Naso C, Marigliano V, et al. Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J. 2002;143:703–10.
   PubMed Web of Science ®Google Scholar
• Adams D, Lozeron P, Theaudin M, Mincheva Z, Cauquil C, Adam C, et al. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid. 2012;19(Suppl 1):61–4.
   PubMed Web of Science ®Google Scholar
• Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain. 2000;123(Pt 7): 1495–504.
   PubMed Web of Science ®Google Scholar
• Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40:242–6.
   PubMed Web of Science ®Google Scholar
• Suhr OB, Ando Y, Holmgren G, Wikström L, Friman S, Herlenius G, et al. Liver transplantation in familial amyloidotic polyneuropathy (FAP). A comparative study of transplanted and non-transplanted patient’s survival. Transpl Int. 1998;11(Suppl 1):S160–3.
   Google Scholar
• Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78:637–43.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant. 2007;7:2597–604.
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Yazaki M, Kametani F, Takei Y, Ikeda S. Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl. 2008;14:563–70.
   PubMed Web of Science ®Google Scholar
• Rydh A, Suhr O, Hietala SO, Ahlstrom KR, Pepys MB, Hawkins PN. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med. 1998;25:709–13.
   PubMedGoogle Scholar
• Wilczek HE, Larsson M, Ericzon BG; FAPWTR. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid. 2011;18(Suppl 1):193–5.
   PubMed Web of Science ®Google Scholar
• Herlenius G, Wilczek HE, Larsson M, Ericzon BG; Familial Amyloidotic Polyneuropathy World Transplant Registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation. 2004;77:64–71.
   PubMed Web of Science ®Google Scholar
• Shimojima Y, Morita H, Kobayashi S, Takei Y, Ikeda S. Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol. 2008; 255:1220–5.
   PubMed Web of Science ®Google Scholar
• Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75:324–7.
   PubMed Web of Science ®Google Scholar
• Ihse E, Suhr OB, Hellman U, Westermark P. Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl). 2011;89:171–80.
   PubMed Web of Science ®Google Scholar
• Olofsson BO, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation. 2002; 73:745–51.
   PubMed Web of Science ®Google Scholar
• Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun. 2000;274:702–6.
   PubMed Web of Science ®Google Scholar
• Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998;66:229–33.
   PubMed Web of Science ®Google Scholar
• Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation. 2012;93:1017–23.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, Sawkar AR, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121:73–85.
   PubMed Web of Science ®Google Scholar
• Sá Couto P, Barros F, Esteves S, Aragão I. Comparison of outcome data after liver transplant: familial amyloid polyneuropathy (Portuguese type) recipients versus classical indications for liver transplant. Eur J Anaesthesiol. 2010;27:13 [Abstract 1AP3-6].
   Google Scholar
• Barreiros AP, Post F, Hoppe-Lotichius M, Linke RP, Vahl CF, Schafers HJ, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl. 2010;16:314–23.
   PubMed Web of Science ®Google Scholar
• Takei Y, Ikeda S, Ikegami T, Hashikura Y, Miyagawa S, Ando Y, et al. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: outcomes of living donor liver transplantations. Intern Med. 2005;44:1151–6.
   PubMed Web of Science ®Google Scholar
• Bispo M, Marcelino P, Freire A, Martins A, Mourao L, Barroso E. High incidence of thrombotic complications early after liver transplantation for familial amyloidotic polyneuropathy. Transpl Int. 2009; 22:165–71.
   PubMed Web of Science ®Google Scholar
• Nowak G, Suhr OB, Wikstrom L, Wilczek H, Ericzon BG. The long-term impact of liver transplantation on kidney function in familial amyloidotic polyneuropathy patients. Transpl Int. 2005;18:111–15.
   PubMed Web of Science ®Google Scholar
• Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg. 2002;236:429–36.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Perugini E, Salvi F, Grigioni F, Riva L, Cooke RM, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid. 2006;13:143–53.
   PubMed Web of Science ®Google Scholar
• Nelson LM, Penninga L, Sander K, Hansen PB, Villadsen GE, Rasmussen A, et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clin Transplant. 2013;27:203–9.
   PubMed Web of Science ®Google Scholar
• Raichlin E, Daly RC, Rosen CB, McGregor CG, Charlton MR, Frantz RP, et al. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009;88:219–25.
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23:1142–53.
   PubMed Web of Science ®Google Scholar
• Rappley I, Monteiro C, Novais M, Baranczak A, Solis G, Wiseman RL, et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry. 2014;53:1993–2006.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, Waddington CM, Planté-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–92.
   PubMed Web of Science ®Google Scholar
• Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6:1011–20.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Judge DP, Rosas GR, Mandel FS, Aarts J. Interim analysis of long-term, open-label tafamidis treatment in transthyretin amyloid cardiomyopathy after up to 5 years of treatment. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April–1 May 2014 [Presentation No. OP-66].
   Google Scholar
• Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D, et al. Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013; 20:1539–45.
   PubMed Web of Science ®Google Scholar
• Castaño A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012;18:315–19.
   PubMedGoogle Scholar
• Obici L, Cortese A, Lozza A, Palladini G, Perlini S, Gobbi M, et al. A phase II study of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidois. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April–1 May 2014 [Abstract OP–68].
   Google Scholar
• Crooke ST. ISIS Pharmaceuticals. J P Morgan Healthcare Conference. Available at: http://www.google.co.uk/url?sa =trct = j&q = &esrc = s&source = web&cd = 3&cad = rja&uact = 8&sqi = 2&ved = 0CD8QFjAC&url = http%3A%2F%2Fwww.buenavistainv.com%2Fdbimages%2FJP%2520Morgan%2520Healthcare%2520%2520Presentation%25201-2013.pdf&ei = TLEqVIK5BoTB7gb87oCYCw&usg = AFQjCNFZE5NPGhbaAN8RwLwZ0K9kbziyZQ&bvm = bv.76477589 (accessed 16 January 2015).
   Google Scholar
• Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–29.
   PubMed Web of Science ®Google Scholar
• Gollob J. Summary data from Phase II ALN-TTR02 RNAi treatment of ATTR. IXth International Symposium on Familial Amyloidotic Polyneuropathy (IFSAP). Rio de Janeiro, Brazil; 10–13 November 2013.
   Google Scholar
• Coelho T, Suhr O, Conceicao I, Wadington-Cruz M, Schmidt H, Buades J, et al. Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic for the treatment of familial amyloid polyneuropathy. 67th Annual Meeting of the American Academy of Neurology (AAN), Washington, DC, USA; 18–25 April 2015 [Abstract S9.003].
   Google Scholar
• Gillmore J, Falk R, Maurer M, Hanna M. Interim results from pilot phase 2 trial of revusiran (ALN-TTRsc). American Heart Association Annual Meeting Scientific Sessions. Chicago, IL, USA; 15–19 November 2014.
   Google Scholar
• Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260: 2802–14.
   PubMed Web of Science ®Google Scholar
• Coelho T, Silva AM, Valdrez K, Cardoso M, Monteiro C, Ferreira H, et al. Familial amyloid polyneuropathy treatment with tafamidis – evaluation of one year treatment at Porto, Portugal. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April–1 May 2014 [Abstract OP-67].
   Google Scholar
• Merlini G, Waddington CM, Stewart M, Rosas GR, Huertas PE, Mandel FS, et al. Survival in patients with transthyretin familial amyloid polyneuropathy receiving tafamidis treatment. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April– 1 May 2014 [Abstract OP-65].
   Google Scholar
• US Food and Drug Administration. Vyndaqel (tafamidis meglumine) – Proposed indication: treatment of transthyretin (TTR) familial amyloid polyneuropathy. Available at: http://www.fda.gov/downloads/AdvisorycommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM304830.pdf (accessed 16 January 2015).
   Google Scholar
• Rocha A, Silva AM, Cardoso M, Monteiro C, Beirão I, Alves C, et al. Treatment of ATTR Val30Met with tafamidis: successful decrease of proteinuria. XIVth International Symposium on Amyloidosis (ISA). Indianapolis, IN, USA; 27 April–1 May 2014.
   Google Scholar
• National Amyloidosis Centre. ATTR Amyloidosis. Available at: http://www.amyloidosis.org.uk/introduction-to-attr-amyloidosis/ (accessed 16 January 2015).
   Google Scholar
• Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004;84:545–52.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13:236–49.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Tojo K, Morita H, Koyama J, Yazaki M, Ikeda S. Safety and efficacy of long-term diflunisal administration in familial amyloid polyneuropathy – Summary of ten years therapeutic experience. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April–1 May 2014 [Abstract OP-70].
   Google Scholar
• Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the1990s. Arch Intern Med.2000;160:2093–9.
   Google Scholar
• Singh BK, Haque SE, Pillai KK. Assessment of nonsteroidal anti- inflammatory drug-induced cardiotoxicity. Expert Opin Drug Metab Toxicol. 2014;10:143–56.
   PubMed Web of Science ®Google Scholar
• Reddy KS, Roy A. Cardiovascular risk of NSAIDs: time to translate knowledge into practice. PLoS Med. 2013;10:e1001389.
   PubMed Web of Science ®Google Scholar
• Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–9.
   PubMed Web of Science ®Google Scholar
• Quarta CC, Falk RH, Soloman SD, Suhr OB, Obici L, Perlini S, et al. The prevalence of cardiac amyloidosis in familial amyloidotic polyneuropathy with predominant neuropathy: The Diflunisal Trial. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April–1 May 2014 [Abstract OP-69].
   Google Scholar
• Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74–84.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in amyloid A amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24–9.
   PubMed Web of Science ®Google Scholar
• Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014;99:209–21.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2006;1:1331–41.
   PubMed Web of Science ®Google Scholar
• Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33:609–18.
   PubMed Web of Science ®Google Scholar
• Ackermann EJ, Guo S, Booten S, Benson M, Hughes S, Monia BP. Clinical development of an antisense therapy for the treatment of hereditary transthyretin amyloidosis. XIIIth International Symposium on Amyloidosis (ISA), Groningen, The Netherlands; 6–10 May 2012 [Abstract OP 73].
   Google Scholar
• Butler JS, Chan A, Costelha S, Fishman S, Milstein S, Willoughby JS, et al. Preclinical evaluation of RNAi therapeutics for the treatment of ATTR: an update. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April–1 May 2014 [Abstract PC-9].
   Google Scholar
• Suhr O, Adams D, Coelho T, Conceicao I, Waddington CM, Schmidt H, et al. Further analysis of phase II trial of patisiran, a novel RNAi therapeutic for the treatment of familial amyloidotic polyneuropathy. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April–1 May 2014 [Abstract OP-72].
   Google Scholar
• European Medicines Agency. Tafamidis EMA assessment report. Available at: http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002294/WC500117838 pdf (accessed 16 January 2015).
   Google Scholar
• Zimmermann T, Karsten V, Harrop J, Chan A, Chiesa J, Peters G, et al. Phase I first-in-human trial of ALN-TTRsc, a novel RNA interference therapeutic for the treatment of familial amyloidotic cardiomyopathy (FAC). Heart Failure Society of America 17th Annual Meeting; Orlando, FL, USA; 22–25 September 2013 [Poster].
   Google Scholar
• Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136:16958–61.
   PubMed Web of Science ®Google Scholar
• Obayashi K, Tasaki M, Jono H, Ueda M, Shinriki S, Misumi Y, et al. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine. Clin Chim Acta. 2013;419:127–31.
   PubMed Web of Science ®Google Scholar
• Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468:93–7.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol. 2010;148:760–7.
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Guendouz S, Damy T, Hulin A. Use of tafamidis in 3 transplanted amyloidosis ATTR-FAP patients: safety and association with immunosuppressive drugs. IXth Congress of Physiology, Pharmacology and Therapeutics, Poitiers, France; 22–24 April 2014 [Abstract PM1-043].
   Google Scholar
• Yoshinaga T, Yazaki M, Sekijima Y, Kametani F, Ikeda S. Regression of gastroduodenal mucosal amyloid deposits in FAP patients after combined therapy with oral intake of diflunisal followed by liver transplantation. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April–1 May 2014 [Abstract OP-77].
   Google Scholar